ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like Cambridge-Based Biotech Scoops Up $46.7 Million in Funding Round October 4, 2017 European Regulators Make Decisions on Several Companies’ Drugs February 25, 2018 Buyers Remorse: Merck & Co. Takes $2.9 Billion Charge on Hepatitis C Drug Inherited From $3.9 Billion Idenix Buy February 23, 2017
Buyers Remorse: Merck & Co. Takes $2.9 Billion Charge on Hepatitis C Drug Inherited From $3.9 Billion Idenix Buy February 23, 2017
